Opus Genetics (IRD) Loans and Notes Receivables (2010 - 2019)

Opus Genetics (IRD) reported Loans and Notes Receivables of $50000.0 for Q4 2019, up 970.43% quarter-over-quarter from $4671.0 in Q2 2012.

Opus Genetics (IRD) Loans and Notes Receivables (2010 - 2019) Analysis & Trends

Opus Genetics (IRD) has 4 years of Loans and Notes Receivables data on file, last reported at $50000.0 in Q4 2019.

Loans and Notes Receivables for Q4 2019 came in at $50000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $50000.0 (changed N/A YoY), and the FY2019 annual result was $50000.0, changed N/A from the prior year.
Loans and Notes Receivables rose to $50000.0 in Q4 2019 per IRD's latest filing, from $4671.0 in the prior quarter.
Over five years, Loans and Notes Receivables peaked at $50000.0 in Q4 2019 and troughed at $50000.0 in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Loans & Notes Receiv. (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	-
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Opus Genetics	349.74 Mn	289.78 Mn	-	-

Download Data